COVID-19治疗:英格兰的抗菌药物管理及抗菌药物耐药性考量
本文阐述英格兰在COVID-19疫情期间为直接作用抗病毒药物(DAA)实施的管理与监测活动,包括流行病学、病毒学和基因组监测,以评估这些药物的部署、安全性、有效性及耐药潜力。
要点
- 英格兰快速实施抗菌药物管理和监测以保护DAA活性并检测耐药突变。
- 公共卫生活动包括流行病学、病毒学和基因组监测。
- 监测支持评估DAA的部署、安全性、有效性和耐药潜力。
核心结论
- 为保护COVID-19治疗用DAA的活性并检测可能的耐药突变,英格兰快速实施了抗菌药物管理和监测。
研究设计与样本
- 本文为综述,阐述英格兰正在进行的公共卫生活动,包括流行病学、病毒学和基因组监测。
主要发现
- DAA无疑预防了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染者的疾病进展和危及生命的状况。
- 对DAA存在抗菌药物耐药性(AMR)的担忧,特别是抗病毒耐药性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.
引用
- Bou-Antoun S, Rokadiya S, Ashiru-Oredope D, et al. COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance. J Antimicrob Chemother. 2023. PMID: 37995354. doi:10.1093/jac/dkad314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。